Research Article Details
| Article ID: | A49384 |
| PMID: | 35767969 |
| Source: | Ann Nutr Metab |
| Title: | Reversal of diabesity: Normalization of insulin release curve in association with reversal of non-alcoholic fatty liver disease. |
| Abstract: | OBJECTIVE: Type 2 diabetes with obesity is regarded as an incurable, progressive disease with many complications. The hypothesis was tested that HbA1c and the insulin release curve can be restored by traceable systematic methods. METHODS: 122 people with diabesity were investigated before and after three and six months of traceable systematic management methods. Basal BMI, fatty liver, HbA1c and insulin release curve were measured. RESULTS: After three months of traceable systematic management, BMI decreased from 30.76 ± 0.48 to 21.86 ± 0.09 kg/m2 (p <0.001), and remained stable during the last three months (21.82 ± 0.09 kg/m2 at six months). Colour Doppler ultrasound showed non-alcoholic fatty liver disease (NAFLD) in all diabesity participants at baseline. At three months, only one participant had low-grade fatty liver, and fatty liver was reversed in other participants (p <0.001). The number and grade of fatty liver at six months were the same as at three months. And fasting plasma glucose decreased and continued to decrease thereafter (p <0.001). Two hours postprandial plasma glucose decreased and continued to decline until six months (p <0.001). HbA1c also decreased and maintained this level at six months. At baseline, the peak value of insulin release was 1141.09 ± 43.02 pmol/L at two hours after meals, and the early phase of insulin secretion was lost. After three months of management, the insulin concentration was 621.62±19.32 pmol/L at two hours after meals. After six months, the value decreased and the early phase of insulin secretion recovered. CONCLUSIONS: Normalization of the insulin release curve in type 2 diabetes was achieved by traceable systematic methods. This was associated with recovery from NAFLD. Diabesity is reversible by traceable systematic management. |
| DOI: | 10.1159/000525734 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |